This week saw both Regenxbio and Solid Bio report new data with their gene therapy candidates for Duchenne muscular dystrophy ...

Immutep's ASX-listed stock fell more than 88% on the news that its phase 3 trial TACTI-004 of LAG-3 inhibitor eftilagimod alfa (efti) as a first-line treatment for non-small cell lung cancer (NSCLC) ...

Eisai has launched a campaign to raise awareness of sleep disorders in Japan, via a partnership with smartphone app Pokémon ...

The pharmaceutical and biotech sectors have seen a flurry of executive movement this month, with leadership changes spanning global giants, clinical-stage biotechs, and specialist pharma companies ...

Hospitals in England have been urged to block the implementation of software developed by controversial tech firm Palantir by a coalition of patient, healthcare, worker, trade union, and consumer ...

Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...

Many Americans are forced to make difficult trade-offs with living expenses and delay life events like retirement to afford health, says a new poll. The Gallup/West Health survey (PDF) of around ...

They are due to leave by the end of this year to set up an as-yet unnamed "independent biotechnology company to research and ...

Steve Sanghera is the CEO and co-founder of Inventus. With over 20 years of experience in technology and telecommunications, ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

The consequences of the US-Israel war in Iran have spilled over into the medtech sector, with a cyberattack launched against prominent US company Stryker. An Iranian hacker group has claimed ...

Evotec has announced the next phase of its company overhaul, dubbed Horizon, that will see 800 people lose their jobs in a bid to cut €75 million in costs by the end of 2027. The layoffs follow around ...